Sanofi-Aventis Will Enter U.S. OTC Market By Paying $1.9 Billion For Chattem
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.
The deal, which is Sanofi's latest attempt to diversity in the face of a looming patent cliff, provides a platform for Rx-to-OTC switches.